| Literature DB >> 32235725 |
Taejoon Kim1, Bokyeong Song1, Kyoung Sang Cho1, Im-Soon Lee1.
Abstract
Forest trees are a major source of biogenic volatile organic compounds (BVOCs). Terpenes and terpenoids are known as the main BVOCs of forest aerosols. These compounds have been shown to display a broad range of biological activities in various human disease models, thus implying that forest aerosols containing these compounds may be related to beneficial effects of forest bathing. In this review, we surveyed studies analyzing BVOCs and selected the most abundant 23 terpenes and terpenoids emitted in forested areas of the Northern Hemisphere, which were reported to display anti-inflammatory activities. We categorized anti-inflammatory processes related to the functions of these compounds into six groups and summarized their molecular mechanisms of action. Finally, among the major 23 compounds, we examined the therapeutic potentials of 12 compounds known to be effective against respiratory inflammation, atopic dermatitis, arthritis, and neuroinflammation among various inflammatory diseases. In conclusion, the updated studies support the beneficial effects of forest aerosols and propose their potential use as chemopreventive and therapeutic agents for treating various inflammatory diseases.Entities:
Keywords: BVOC; anti-inflammation; forest aerosol; terpene; terpenoid
Mesh:
Substances:
Year: 2020 PMID: 32235725 PMCID: PMC7139849 DOI: 10.3390/ijms21062187
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
General types of terpenes and terpenoids emitted from forested areas. Some of the well-known synonyms and molecular formulas are shown in brackets. All structures of the compounds are from the PubChem 3D viewer database (https://pubchem.ncbi.nlm.nih.gov), in which carbons and oxygens are colored in gray and red, respectively. For more details on the drawing, refer to the description in the Pubchem web site (https://pubchem.ncbi.nlm.nih.gov/pc3d/PC3DView1.html).
| Type | Name (Synonym, Molecular Formula) | Ref | |||
|---|---|---|---|---|---|
| Monoterpene | α-Pinene | β-Pinene | 3-Carene | d-Limonene | [ |
|
|
|
|
| ||
| Camphene | Myrcene | α-Terpinene | γ-Terpinene | ||
|
|
|
|
| ||
| α-Phellandrene | β-Phellandrene | p-Cymene | Sabinene | ||
|
|
|
|
| ||
| Terpinolene | |||||
| Oxygenated monoterpene | 1,8-Cineole | Camphor | Borneol | α-Terpineol | [ |
|
|
|
|
| ||
| Terpinen-4-ol | Linalool | Linalool-oxide | |||
|
|
|
| |||
| Monoterpene derivatives | Bornyl acetate | [ | |||
|
| |||||
| Sesquiterpene | Humulene | β-Caryophyllene | [ | ||
|
|
| ||||
The anti-inflammatory activities of the major 23 terpenes and terpenoids emitted in the forests and their action mechanisms.
| Related Inflammatory Activities | Name | Mechanism of Action | Experimental Protocol | Animal Tested | Ref. |
|---|---|---|---|---|---|
|
|
| TNF-α, IL-1β and IL-6 ↓ | LPS-stimulation | Raw 264.7 cell line | [ |
| NF-kB, COX-2, iNOS and Nitrite levels ↓ | Doxorubicin-induced inflammation | Wistar rats | [ | ||
| NO levels ↓ | Aβ42 expressed heads | Fruit fly | [ | ||
| NO and iNOS levels ↓ | In vitro treatment | Human chondrocytes | [ | ||
|
| NO and iNOS levels ↓ | In vitro treatment | Human chondrocytes | [ | |
|
| TNF-α and IL-1β ↓ | Carrageenan-induced peritonitis model | Swiss mice | [ | |
| IL-1β, IL-6↓ and IL-10, COX-2, PGE2 ↑ | LPS-Stimulation | Macrophages from mice | [ | ||
|
| TNF-α and IL-6 ↓ | Carrageenan injection in air pouch cavities | Wistar rats or swiss mice | [ | |
| IL-6 and TNF-α ↓ NO production ↓ | LPS-stimulation | Raw 264.7 cell line | [ | ||
|
| Pro-inflammatory cytokines IL-6 and TNF-α ↓ | LPS-stimulation | Raw 264.7 cell line | [ | |
|
| Production of LTB4 and PGE2 from monocytes ex vivo | Stimulated with the calcium ionophore A23187 measured ex vivo | Blood monocytes of patients with bronchial asthma | [ | |
| TNF-α and IL-1β, leukotriene B4 and thromboxane B2 ↓ | LPS-and IL1β-stimulation in vitro | Human monocytes | [ | ||
| Levels of TNFα and IL-1β in BALF ↓ | Experimental model of airways | Ovalbumin (OVA)-challenged | [ | ||
| TNF-α and IL-1β ↓ and IL-10 ↑ | Mouse LPS-induced acute lung injury model | ICR mice | [ | ||
| NO ↓ TNF-α, IL-1β and IL-6 ↓ | Aβ (25-35) treatment | PC 12 cell line | [ | ||
| MMP-9 ↓ TNF-α, IL-6 and NO ↓ | LPS-induced acute lung injury mouse model | BALB/C mice | [ | ||
| Production of interleukin IL-4, IL-13 and IL-17A in BALF after Derp challenge ↓ | House dust mite (HDM)- induced | BEAS-2B cell line | [ | ||
| IL-1β, IL-6 and TNF-α in BALF ↓ | Short-term cigarette smoke (CS) exposure | C57BL/6 mice | [ | ||
| IL-4, IL-5, IL-10, and MCP-1 in nasal lavage fluids ↓ | Mice infected with influenza A virus | BALB/C mice | [ | ||
|
| TNF-α, IL-1β and IL-6 in Kidney, testes, liver and lung ↑ | An acute administration | Wistar rats | [ | |
|
| IL-1β and IL-6 mRNA expression in colon tissue ↓ | TNBS-induced colitis | ICR mouse | [ | |
| The elevation of NO, the increase of inducible iNOS enzymatic activity and the upregulation of iNOS expression ↓ | In vitro ischemic model of oxygen-glucose deprivation followed by reperfusion | Wistar rats | [ | ||
| TNF-α, IL-1β, and IL-6 ↓ | Mouse LPS-induced acute lung injury model | Raw 264.7 cell line | [ | ||
| CD16 and CD206 expressions and levels of IL-1β, IL-6, TNF-a, and IL-10 proteins ↓ | LPS-stimulated mouse microglia and septic mice | C57BL/6 mice | [ | ||
|
| Nitrite production ↓ | LPS-stimulation | Peritoneal macrophage | [ | |
|
| NF-κB and NLRP3 inflammasome ↓ | Dextran sulfate sodium-induced colitis | C57BL/6 mice | [ | |
| LPS-induced phosphorylation of IκBα and NF-κB p65 ↓ The expression of PPAR-γ ↑ | Mouse LPS-induced acute lung injury model | BALB/c mice | [ | ||
|
| The production of LPS-induced TNF-α and IL-6 ↓ | LPS-stimulation | Raw 264.7 cell line | [ | |
| LPS-induced TNF-α, IL-1β, NO, and PGE2 ↓ | LPS-stimulated microglia cells. | Murine BV2 cell line | [ | ||
| The levels of the pro-inflammatory markers p38 MAPK, NOS2, COX2 and IL-1β ↓ | Triple transgenic model of Alzheimer’s disease mice | 3xTg-AD mice | [ | ||
| Endotoxin-induced levels of peripheral nitrate/nitrite, IL-1β, IL-18, TNF-α, IFN-γ, and HMGB-1 ↓ | Endotoxin-injection | C57BL/6J mice | [ | ||
| Microgliosis and decreased COX2, IL-1β and Nrf2 markers in the cerebral cortex and hippocampus ↓ | Focal ischemia | Wistar rats | [ | ||
| Levels of iNOS expression in the lung tissues caused by OVA exposure ↓ | Experimental model of airways allergic inflammation | OVA-challenged mice | [ | ||
|
| IL-1β-mediated up-regulation of IL-6, IL-8, MMP-1, and MMP-13 ↓ | In vitro treatment | Human chondrocytes | [ | |
|
| IL-5, CCL11 and leukotriene B4 levels in bronchoalveolar lavage fluid ↓ | Experimental model of airways allergic inflammation | OVA-challenged mice | [ | |
|
| The serum level of IL-6 protein as well as the level of IL-6 mRNA in the tissue ↓ | Dextran sulfate sodium-induced colitis | BALB/c mice | [ | |
| Anti-inflammatory (IL-10, Arg-1, and urea) and anti-oxidant GSH parameters ↑and the inflammatory (IL-1β, TNF-α, PGE2, iNOS and NO) and ROS biomarkers ↓ | LPS-stimulation | Primary microglia cell lines (C57BL/6) | [ | ||
| The elevated TNF-α, NF-κB, and iNOS ↓ | Rats fed a high fat/fructose diet to induce insulin resistance and obesity | Wistar rats | [ | ||
| The iNOS in the lumbar spinal cord ↓ | Experimental autoimmune encephalomyelitis, a murine model of multiple sclerosis | C57BL/6 mice | [ | ||
| Pro-inflammatory cytokines and inflammatory mediators | Rotenone-treated rat model of Parkinson disease | Wistar rats | [ | ||
| Hypoxia-induced cytotoxicity as well as IL-1β, TNF-α and IL-6 ↓ | Hypoxia exposure | Murine BV2 cell line | [ | ||
| TNF-α and IL-1β ↓ | Kainic acid-induced seizure activity and oxidative stress | Mouse model | [ | ||
| NO and PGE2 production ↓ iNOS and COX-2 ↓ | Aβ-treated microglia | Murine BV2 cell line | [ | ||
|
|
| NF-κB ↓ | LPS-stimulation | Mouse peritoneal macrophages | [ |
|
| NF-κB ↓ | LPS-induced acute lung injury | BALB/c mice | [ | |
| Doxorubicin-induced inflammation in kidneys | Wistar rats | [ | |||
| In vitro treatment | Human chondrocytes | [ | |||
|
| NF-κB ↓ | In vitro treatment | Human chondrocytes | [ | |
|
| Nuclear translocation of NF-κB p65 ↓ | LPS-stimulation | U373 and HeLa | [ | |
| The expression of NF-κB p65 ↓ | Mouse LPS-induced acute lung injury model | ICR mice | [ | ||
| LPS-induced acute lung injury mouse model | BALB/C mice | [ | |||
| Short-term cigarette smoke (CS) exposure | C57BL/6 mice | [ | |||
| Mice infected with influenza A virus | BALB/C mice | [ | |||
|
| The expressions of renal, testicular, hepatic and pulmonary NF-kB ↑ | An acute administration in male | Wistar rats | [ | |
|
| Phosphorylation of NF-κB and IκBa ↓ | Mouse LPS-induced acute lung injury model | Raw 264.7 cell line | [ | |
|
| Nuclear Nrf-2 protein translocation ↑ | Pneumonia model infected by | A549 cell line | [ | |
| LPS-induced NF-κB activation ↓ | LPS-stimulated microglia cells. | Murine BV2 cell line | [ | ||
| CS-induced NF-κB activation ↓ | Cigarette smoke -induced acute lung inflammation | C57BL/6 mice | [ | ||
| The activation of NF-κB ↓ | Endotoxin-injection | C57BL/6J mice | [ | ||
| The activation of NF-κB in the lung tissues caused by OVA exposure ↓ | Experimental model of airways allergic inflammation | OVA-challenged mice | [ | ||
|
| The NF-kB and the AP-1 activation ↓ | Experimental model of airways allergic inflammation | OVA-challenged mice | [ | |
|
| Hypoxia-induced the activation of NF-κB ↓ | Cultured microglia under hypoxia | Murine BV2 cell line | [ | |
| Aβ1-42-induced phosphorylation and degradation of IκBα, nuclear translocation of p65, and NF-κB transcriptional activity ↓ | Aβ-treated microglia | Murine BV2 cell line | [ | ||
|
|
| ERK and JNK ↓ | LPS-stimulation | Mouse peritoneal macrophages | [ |
|
| p38, JNK, ERK ↓ | LPS-induced acute lung injury | BALB/c mice | [ | |
| p38 and JNK activation ↓ | In vitro treatment | Human chondrocytes | [ | ||
|
| p38 and JNK activation ↓ | In vitro treatment | Human chondrocytes | [ | |
|
| Phosphorylated JNK in U373 cells ↓ | LPS-stimulation | U373 and HeLa | [ | |
| TREM-1, NLRP3 of the inflammasome ↓ Phosphorylation of the transcription factor NF-κB and p38↓MKP-1 phosphatase, a negative regulator of MAPKs ↓ | LPS-induced the murine lung alveolar macrophage inflammation model | MH-S cell line | [ | ||
| NLRP3 inflammasome activation and pro-inflammatory cytokine productions induced by MSU in ankle tissues in vivo ↓ MSU-induced upregulation of TRPV1 expression in ankle tissues and dorsal root ganglion neurons innervating the ankle ↓ | A mouse model of gout arthritis was established via MSU injection into the ankle joint | BALB/c mice | [ | ||
| Inflammatory cytokines (IL-1β, TNF-α and IL-6) ↓ | LPS-induced pulmonary inflammation | C57BL/6 | [ | ||
|
| Phosphorylation of p38 and JNK ↓ | Mouse LPS-induced acute lung injury model | Raw 264.7 cell line | [ | |
| The activation of M2 macrophages in a STAT3-dependent manner ↑ | DSS-induced colitis | Raw 264.7 cell line | [ | ||
| NF-κB and p38 signaling ↓ | LPS-stimulated microglia | C57BL/6 mice | [ | ||
| TRPA1 mediated cationic currents ↓ | In vitro treatment | In heterologous expression systems like Xenopus oocytes and in neurons cultured from trigeminal ganglia | [ | ||
|
| Phosphorylation of IκBα protein, p38, c-JNK, and ERK ↓ | LPS-stimulation | Raw 264.7 cell line | [ | |
|
| Functional agonist of CB(2)R | LPS-stimulation | CB2-expressiong | [ | |
| Activation of ERK 1/2, NF-κB, IκB-kinase α/β ↓ | DSS-induced colitis | CD1 mice | [ | ||
| Cisplatin-induced renal inflammatory response (chemokines MCP-1 and MIP-2, cytokines TNF-α and IL-1β, adhesion molecule ICAM-1, and neutrophil and macrophage infiltration) through a CB(2)R-dependent pathway ↓ | Cisplatin-induced nephropathy model | C57BL/6J | [ | ||
| Activation of NF-κB and the secretion of inflammatory cytokines ↓ | Hypoxia exposure | Murine BV2 cell line | [ | ||
|
|
| ROS formation and lipid peroxidation induced by H2O2-stimulated oxidative damage ↓ | H2O2-stimulated oxidative stress | U373-MG cells | [ |
|
| ROS formation/ caspase-3/caspase-9 activation/p38 MAPK phosphorylation ↓ | H2O2-stimulated oxidative stress | Human lens | [ | |
| Catalase and peroxidase activities of cell antioxidant enzymes ↑ | Lymphoid cell suspensions from lymph nodes | BALB/c mice | [ | ||
|
| Strong antioxidant effect and high scavenging activities against different free radicals | The nonenzymatic antioxidant capacity | Swiss mice | [ | |
| The cell viability and GSH content and restored the mitochondrial membrane potential ↑ NO release and ROS generation ↓ | t-BHP stressed | Wistar rats | [ | ||
|
| ROS, MMP-1, MMP-3, and IL-6, and increased TGF 1 and type I procollagen secretions ↓ The phosphorylation of various MAPK-related signaling molecules ↓ | In vitro treatment | UVB-irradiated human dermal fibroblasts | [ | |
|
| The best antioxidant compounds in ABTS, chelating power and DPPH assays | In vitro antioxidation assay | [ | ||
|
| The best antioxidant compounds in ABTS and DPPH assays | In vitro antioxidation assay | [ | ||
|
| The intracellular oxidative stress environment ↓ | Mice leukemia | WEHI-3 cell line | [ | |
| O2-production ↓ | LPS-stimulation | Raw 264.7 cell line | [ | ||
|
| SOD and catalase activity significantly ↑ | Intraperitoneal treatment with 0.05% Tween 80 | Swiss mice | [ | |
|
| O2-production ↓ | LPS-stimulation | Raw 264.7 cell line | [ | |
|
| ROS formation and lipid peroxidation induced by H2O2-stimulated oxidative damage ↓ | H2O2-stimulated oxidative stress | U373-MG cells | [ | |
|
| Excessive ROS production and mitochondrial impairment ↑ | Oxidative stress-mediated apoptotic cell death |
| [ | |
|
| The best antioxidant compounds in ORAC and Chelating power assay | In vitro antioxidation assay | [ | ||
| Oxidative stress and mitochondrial dysfunction mediated by glutamate and NMDA toxicity ↓ | Oxidative stress and | HT-22 cells | [ | ||
|
| H2O2-induced astrocytic cell death ↓ | Primary astrocytes from cerebral cortices | Neonatal wistar rats | [ | |
|
| H2O2-induced astrocytic cell death ↓ | Primary astrocytes from cerebral cortices | Neonatal wistar rats | [ | |
| Rates of ROS production and the associated respiratory activity in freshly isolated hepatic mitochondria ↓ | Development of adjuvant arthritis | Holtzman rats | [ | ||
|
|
| Expression of apoptosis and autophagy-related genes ↑ | In vitro and vivo treatment | BALB/c mice | [ |
| LC3 lipidation ↑ and clonogenic capacity ↓ | In vitro treatment | SH-SY5Y, HepG2 and MCF7 cell lines | [ | ||
| LC3 II↑ and p62 levels ↓ | In vitro treatment | SH-SY5Y and MCF7 cell lines | [ | ||
|
| Autophagolysosomes ↑ and proliferation ↓ | In vitro treatment | A2780 ovarian and MCF7 and MDAMB231 breast | [ | |
| Autophagy with materials containing Ru complex ↑ | In vitro treatment | B16 and B16-F10 cell lines | [ | ||
|
| Autophagy and apoptotic cell death ↑ | In vitro treatment |
| [ | |
|
| LC3 II/I, pAMPK, mTOR, and ULK1 in hypothalamus, and pAMPK, mTOR, ULK1, Beclin1, and Bax in striatum ↑ | Surgical induction of GCIR | Sprague-Dawley rats | [ | |
| Cortex autophagy by modulating pAMPK in the pAMPK-mammalian target of mTOR-ULK1 signaling pathway ↑ | [ | ||||
|
| E1, p62, and ubiquitin levels ↓ | In vitro treatment | HepG2 cell line | [ | |
|
|
| Sleep enhancing property through a direct binding to GABAA BZD receptors | Pentobarbital-induced sleep | ICR and C57BL/6N mice | [ |
| G2/M-phase cell cycle arrest | In vitro treatment | HepG2 cell line | [ | ||
|
| sleep duration ↑ and sleep latency ↓ | Pentobarbital-induced sleep | ICR and C57BL/6N mice | [ | |
|
| Acetylcholinesterase activities ↓ | In vitro antioxidation assay | [ | ||
|
| Lipoxygenase ↓ | In vitro antioxidation assay | [ | ||
|
| Lipoxygenase ↓ | In vitro antioxidation assay | [ | ||
|
| VCAM-1 ↓, and restored vascular eNOS/iNOS expression balance | high fat/fructose diet-induced dyslipidemia and vascular inflammation | Wistar rats | [ | |
↓ denotes decreased activity; ↑ denotes increased activity.